EUVIMEDEUVIMED entdecken
Crossref

The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer

Meiqi Xu, Menyuan Wu, Feng Pei, Zhenming Pan, Kailai Chen, Xi Chen, Shiyao Xu, Li Zhong, Zhichong Wu, Xiang Pan, Bin Sun, Manjie Zhang und 1 weitere

Cancer Communications · 02.11.2026

DOI: 10.34133/cancomm.0071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 02.11.2026. Verfasst von Meiqi Xu und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Xu, M., Wu, M., Pei, F., Pan, Z., Chen, K., Chen, X., Xu, S., Zhong, L., Wu, Z., Pan, X., Sun, B., Zhang, M., & Luo, Y. (2026). The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer. Cancer Communications. https://doi.org/10.34133/cancomm.0071

Vancouver

Xu M, Wu M, Pei F, Pan Z, Chen K, Chen X, et al. The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer. Cancer Communications. 2026. doi:10.34133/cancomm.0071

BibTeX
@article{Xu2026,
  author = {Xu, Meiqi and Wu, Menyuan and Pei, Feng and Pan, Zhenming and Chen, Kailai and Chen, Xi and Xu, Shiyao and Zhong, Li and Wu, Zhichong and Pan, Xiang and Sun, Bin and Zhang, Manjie and Luo, Yakun},
  title = {The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer},
  journal = {Cancer Communications},
  year = {2026},
  doi = {10.34133/cancomm.0071}
}
Kostenlos starten →